应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
CLRB Cellectar Biosciences Inc.
耶稣受难日休市 03-28 16:00:00 EDT
3.98
+0.35
+9.49%
盘后
4.05
+0.07
+1.76%
19:59 EDT
最高
4.07
最低
3.79
成交量
176.92万
今开
3.83
昨收
3.64
日振幅
7.70%
总市值
1.28亿
流通市值
9,798万
总股本
3,226万
成交额
694.50万
换手率
7.19%
流通股本
2,462万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Cellectar Biosciences, Inc.盘中异动 股价大涨7.02%
自选股智能写手 · 03-28 21:32
Cellectar Biosciences, Inc.盘中异动 股价大涨7.02%
Cellectar Biosciences, Inc.2023财年实现净利润-37.98百万美元,同比减少32.80%
自选股智能写手 · 03-28 06:13
Cellectar Biosciences, Inc.2023财年实现净利润-37.98百万美元,同比减少32.80%
Cellectar Biosciences, Inc.盘中异动 股价大跌5.33%
自选股智能写手 · 03-27 21:32
Cellectar Biosciences, Inc.盘中异动 股价大跌5.33%
Cellectar 生物科学公司公布截至 12 月的季度业绩 - 收益摘要
Reuters · 03-27 21:31
Cellectar 生物科学公司公布截至 12 月的季度业绩 - 收益摘要
Cellectar Biosciences Inc 预计每股亏损 57 美分 - 财报前瞻
Reuters · 03-25
Cellectar Biosciences Inc 预计每股亏损 57 美分 - 财报前瞻
Cellectar Biosciences, Inc.盘中异动 股价大涨5.17%
自选股智能写手 · 03-23
Cellectar Biosciences, Inc.盘中异动 股价大涨5.17%
Cellectar Biosciences, Inc.盘中异动 股价大涨8.36%
自选股智能写手 · 03-19
Cellectar Biosciences, Inc.盘中异动 股价大涨8.36%
Cellectar Biosciences, Inc.盘中异动 下午盘快速下挫5.25%
自选股智能写手 · 03-12
Cellectar Biosciences, Inc.盘中异动 下午盘快速下挫5.25%
Cellectar Biosciences, Inc.盘中异动 临近收盘股价大跌5.13%报4.02美元
自选股智能写手 · 03-06
Cellectar Biosciences, Inc.盘中异动 临近收盘股价大跌5.13%报4.02美元
Cellectar Biosciences, Inc.盘中异动 急速上涨5.95%
自选股智能写手 · 03-04
Cellectar Biosciences, Inc.盘中异动 急速上涨5.95%
Cellectar Biosciences, Inc.盘中异动 早盘大幅拉升5.10%
自选股智能写手 · 03-02
Cellectar Biosciences, Inc.盘中异动 早盘大幅拉升5.10%
Cellectar Biosciences Inc盘中异动 快速上涨5.03%报4.08美元
自选股智能写手 · 02-29
Cellectar Biosciences Inc盘中异动 快速上涨5.03%报4.08美元
Cellectar Biosciences Inc盘中异动 快速上涨5.15%报3.67美元
自选股智能写手 · 02-27
Cellectar Biosciences Inc盘中异动 快速上涨5.15%报3.67美元
Cellectar Biosciences Inc盘中异动 早盘急速上涨5.04%报3.44美元
自选股智能写手 · 02-22
Cellectar Biosciences Inc盘中异动 早盘急速上涨5.04%报3.44美元
Cellectar Biosciences Inc盘中异动 快速下挫5.08%
自选股智能写手 · 02-21
Cellectar Biosciences Inc盘中异动 快速下挫5.08%
Cellectar Biosciences Inc盘中异动 下午盘股价大涨5.31%报3.57美元
自选股智能写手 · 02-15
Cellectar Biosciences Inc盘中异动 下午盘股价大涨5.31%报3.57美元
Cellectar Biosciences Inc盘中异动 下午盘快速下跌5.00%
自选股智能写手 · 02-14
Cellectar Biosciences Inc盘中异动 下午盘快速下跌5.00%
Cellectar Biosciences Inc盘中异动 股价大跌5.05%报3.57美元
自选股智能写手 · 02-05
Cellectar Biosciences Inc盘中异动 股价大跌5.05%报3.57美元
Cellectar Biosciences Inc盘中异动 股价大跌5.34%报3.72美元
自选股智能写手 · 02-02
Cellectar Biosciences Inc盘中异动 股价大跌5.34%报3.72美元
Cellectar Biosciences Inc盘中异动 股价大跌5.23%
自选股智能写手 · 01-31
Cellectar Biosciences Inc盘中异动 股价大跌5.23%
加载更多
公司概况
公司名称:
Cellectar Biosciences Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Cellectar Biosciences, Inc.以前名为Novelos Therapeutics, Inc.于1996年6月成立于特拉华州。2014年2月11日,公司更名为现在的名字。它是一家生物制药公司,开发用于治疗肿瘤成像化合物。该公司的癌症靶向技术允许选择性递送的多种剂对癌症细胞,包括癌症干细胞。该公司目前正在开发三种专利的候选产品:I-124-CLR1404 是一种小分子,广谱,肿瘤的靶向性的正电子发射断层扫描(PET)显像剂,该公司认为其必须在范围广泛的癌症肿瘤和转移的选择性检测的第一种可能。I-131-CLR1404是一种小分子,广谱,癌靶向分子放射治疗的直接和选择性地提供细胞毒性(细胞杀伤)辐射到癌细胞和癌干细胞。CLR1502是一种临床前,小分子,肿瘤靶向,非放射性的光学成像术中肿瘤边缘照明和非侵入性的肿瘤成像剂。
发行价格:
--
{"stockData":{"symbol":"CLRB","market":"US","secType":"STK","nameCN":"Cellectar Biosciences Inc.","latestPrice":3.98,"timestamp":1711656000000,"preClose":3.635,"halted":0,"volume":1769204,"hourTrading":{"tag":"盘后","latestPrice":4.05,"preClose":3.98,"latestTime":"19:59 EDT","volume":10003,"amount":40493.8028,"timestamp":1711670395668},"delay":0,"floatShares":24616900,"shares":32260500,"eps":-3.11,"marketStatus":"耶稣受难日休市","marketStatusCode":7,"change":0.345,"latestTime":"03-28 16:00:00 EDT","open":3.83,"high":4.07,"low":3.79,"amount":6944953.687472,"amplitude":0.077029,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.11,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1711958400000},"adr":0,"adjPreClose":3.635,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":3.89,"preClose":3.635,"latestTime":"09:27 EDT","volume":69512,"amount":259232.526596,"timestamp":1711632470063},"postHourTrading":{"tag":"盘后","latestPrice":4.05,"preClose":3.98,"latestTime":"19:59 EDT","volume":10003,"amount":40493.8028,"timestamp":1711670395668},"volumeRatio":1.55661556266504},"requestUrl":"/m/hq/s/CLRB","defaultTab":"news","newsList":[{"id":"2422419414","title":"Cellectar Biosciences, Inc.盘中异动 股价大涨7.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422419414","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422419414?lang=zh_cn&edition=full","pubTime":"2024-03-28 21:32","pubTimestamp":1711632730,"startTime":"0","endTime":"0","summary":"北京时间2024年03月28日21时32分,Cellectar Biosciences, Inc.股票出现波动,股价急速拉升7.02%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.13%。其相关个股中,Avalo Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Nutriband Inc C/Wts 涨幅较大,Avalo Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Ibio, Inc.较为活跃,换手率分别为359.94%、289.00%、261.08%,振幅较大的相关个股有Avalo Therapeutics, Inc.、Nutriband Inc C/Wts 、Psyence Biomedical Ltd C/Wts 25/01/2029,振幅分别为52.63%、41.04%、31.00%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403282132108b6dfc2a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403282132108b6dfc2a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422920760","title":"Cellectar Biosciences, Inc.2023财年实现净利润-37.98百万美元,同比减少32.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422920760","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422920760?lang=zh_cn&edition=full","pubTime":"2024-03-28 06:13","pubTimestamp":1711577595,"startTime":"0","endTime":"0","summary":"12月31日,Cellectar Biosciences, Inc.公布财报,公告显示公司2023财年净利润为-37.98百万美元,同比减少32.80%;其中营业收入为0.00美元,每股基本收益为-3.11美元。从资产负债表来看,Cellectar Biosciences, Inc.总负债13.43百万美元,其中短期债务58979.00美元,资产负债比为0.90,流动比率为0.81。机构评级:截至2023年12月31日,当前有4家机构对Cellectar Biosciences, Inc.目标价做出预测,其中目标均价为14.75美元,其中最低目标价为7.00美元,最高目标价为28.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403280613218b6b1a72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403280613218b6b1a72&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422199741","title":"Cellectar Biosciences, Inc.盘中异动 股价大跌5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422199741","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422199741?lang=zh_cn&edition=full","pubTime":"2024-03-27 21:32","pubTimestamp":1711546336,"startTime":"0","endTime":"0","summary":"北京时间2024年03月27日21时32分,Cellectar Biosciences, Inc.股票出现波动,股价大幅跳水5.33%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.34%。其相关个股中,Ibio, Inc.、Lixte Biotechnology Holdings, Inc.、Lixte Biotechnology Holdings Inc C/Wts 30/11/2025 涨幅较大,Ibio, Inc.、Lixte Biotechnology Holdings, Inc.、Hoth Therapeutics, Inc.较为活跃,换手率分别为877.64%、392.13%、48.75%,振幅较大的相关个股有Ibio, Inc.、Lixte Biotechnology Holdings, Inc.、Annexon, Inc.,振幅分别为32.17%、19.73%、15.19%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272132177a4f874b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272132177a4f874b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422499293","title":"Cellectar 生物科学公司公布截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2422499293","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422499293?lang=zh_cn&edition=full","pubTime":"2024-03-27 21:31","pubTimestamp":1711546273,"startTime":"0","endTime":"0","summary":" * Cellectar Biosciences Inc 报告,截至12月底的季度调整后每股亏损61美分,低于去年同期的每股收益-55美分。四位分析师对该季度的平均预期是每股亏损 57 美分。华尔街的预期在每股-78美分到-39美分之间。* Cellectar Biosciences Inc 报告的季度每股收益为亏损 61 美分。* 公司当季亏损 745 万美元。* Cellectar Biosciences Inc 的股价本季度上涨了 39.0%。* 医药同行的平均一致建议是 \"买入\"。华尔街对 Cellectar Biosciences Inc 的 12 个月目标价中位数为 12.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422751148","title":"Cellectar Biosciences Inc 预计每股亏损 57 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2422751148","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422751148?lang=zh_cn&edition=full","pubTime":"2024-03-25 20:41","pubTimestamp":1711370503,"startTime":"0","endTime":"0","summary":" * Cellectar Biosciences Inc 将于3月27日公布截至2023年12月31日的财报,预计该公司的季度收入将保持不变。* * LSEG分析师对Cellectar Biosciences Inc的平均预期是每股亏损57美分。* 华尔街对 Cellectar Biosciences Inc 的 12 个月目标价中位数为 12.00 美元,高于其最新收盘价 4.05 美元。3月25日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2421318828","title":"Cellectar Biosciences, Inc.盘中异动 股价大涨5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2421318828","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421318828?lang=zh_cn&edition=full","pubTime":"2024-03-23 01:29","pubTimestamp":1711128557,"startTime":"0","endTime":"0","summary":"北京时间2024年03月23日01时29分,Cellectar Biosciences, Inc.股票出现波动,股价急速拉升5.17%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.09%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。其领先的PDC治疗,iopofosine是一种小分子PDC,旨在提供碘-131直接靶向传输到癌细胞,同时限制其暴露于健康细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403230129177a4e8e84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403230129177a4e8e84&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420222950","title":"Cellectar Biosciences, Inc.盘中异动 股价大涨8.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420222950","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420222950?lang=zh_cn&edition=full","pubTime":"2024-03-19 21:31","pubTimestamp":1710855096,"startTime":"0","endTime":"0","summary":"北京时间2024年03月19日21时31分,Cellectar Biosciences, Inc.股票出现异动,股价快速拉升8.36%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.05%。其相关个股中,Fusion Pharmaceuticals Inc.、Enveric Biosciences, Inc.、Hoth Therapeutics, Inc.涨幅较大,Enveric Biosciences, Inc.、Hoth Therapeutics, Inc.、Clearmind Medicine Inc.较为活跃,换手率分别为432.74%、142.24%、117.41%,振幅较大的相关个股有Enveric Biosciences, Inc.、Salarius Pharmaceuticals, Inc.、Lantern Pharma Inc.,振幅分别为17.27%、11.59%、11.23%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403192131368b4801aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403192131368b4801aa&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2418839734","title":"Cellectar Biosciences, Inc.盘中异动 下午盘快速下挫5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2418839734","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2418839734?lang=zh_cn&edition=full","pubTime":"2024-03-12 03:13","pubTimestamp":1710184391,"startTime":"0","endTime":"0","summary":"北京时间2024年03月12日03时13分,Cellectar Biosciences, Inc.股票出现波动,股价大幅下挫5.25%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.17%。其相关个股中,Aslan Pharmaceuticals Limited、Tc Biopharm Plc C/Wts 10/02/2028 、Tc Biopharm Plc涨幅较大,Tc Biopharm Plc、180 Life Sciences Corp.、Transcode Therapeutics, Inc.较为活跃,换手率分别为5627.43%、194.75%、118.08%,振幅较大的相关个股有Aslan Pharmaceuticals Limited、Tc Biopharm Plc、Tc Biopharm Plc C/Wts 10/02/2028 ,振幅分别为179.84%、152.82%、145.83%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403120313117a4ba01d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403120313117a4ba01d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417244264","title":"Cellectar Biosciences, Inc.盘中异动 临近收盘股价大跌5.13%报4.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2417244264","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2417244264?lang=zh_cn&edition=full","pubTime":"2024-03-06 04:38","pubTimestamp":1709671139,"startTime":"0","endTime":"0","summary":"北京时间2024年03月06日04时38分,Cellectar Biosciences, Inc.股票出现异动,股价急速下跌5.13%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为1.51%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。其领先的PDC治疗,iopofosine是一种小分子PDC,旨在提供碘-131直接靶向传输到癌细胞,同时限制其暴露于健康细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030604385987e7627c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030604385987e7627c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2416742141","title":"Cellectar Biosciences, Inc.盘中异动 急速上涨5.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416742141","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416742141?lang=zh_cn&edition=full","pubTime":"2024-03-04 22:30","pubTimestamp":1709562629,"startTime":"0","endTime":"0","summary":"北京时间2024年03月04日22时30分,Cellectar Biosciences, Inc.股票出现异动,股价快速拉升5.95%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.00%。其相关个股中,Quoin Pharmaceuticals Ltd、Jaguar Health, Inc.、89Bio, Inc.涨幅较大,Quoin Pharmaceuticals Ltd、Jaguar Health, Inc.、Gri Bio, Inc.较为活跃,换手率分别为826.84%、110.20%、42.48%,振幅较大的相关个股有冠科美博、Onconetix, Inc.、Shattuck Labs, Inc.,振幅分别为5.26%、4.56%、3.94%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403042230297a4950ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403042230297a4950ca&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2416623997","title":"Cellectar Biosciences, Inc.盘中异动 早盘大幅拉升5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416623997","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416623997?lang=zh_cn&edition=full","pubTime":"2024-03-02 00:19","pubTimestamp":1709309979,"startTime":"0","endTime":"0","summary":"北京时间2024年03月02日00时19分,Cellectar Biosciences, Inc.股票出现波动,股价快速上涨5.10%。Cellectar Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为2.44%。其相关个股中,Biovie Inc.、Adial Pharmaceuticals, Inc、Cardiff Oncology, Inc.涨幅较大,Adial Pharmaceuticals, Inc、Enveric Biosciences, Inc.、Jaguar Health, Inc.较为活跃,换手率分别为3701.97%、401.88%、335.05%,振幅较大的相关个股有Biovie Inc.、Pasithea Therapeutics Corp C/Wts 12/08/2026 、Jaguar Health, Inc.,振幅分别为96.77%、81.48%、81.19%。Cellectar Biosciences, Inc.公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240302001940861da998&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240302001940861da998&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2415537783","title":"Cellectar Biosciences Inc盘中异动 快速上涨5.03%报4.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2415537783","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2415537783?lang=zh_cn&edition=full","pubTime":"2024-02-29 00:50","pubTimestamp":1709139058,"startTime":"0","endTime":"0","summary":"北京时间2024年02月29日00时50分,Cellectar Biosciences Inc股票出现异动,股价大幅上涨5.03%。Cellectar Biosciences Inc股票所在的生物技术行业中,整体跌幅为0.56%。其相关个股中,Vivani Medical Inc、Adial Pharmaceuticals Inc、Vtv Therapeutics Inc涨幅较大,Adial Pharmaceuticals Inc、Vivani Medical Inc、Revelation Biosciences Inc较为活跃,换手率分别为5126.61%、206.11%、83.98%,振幅较大的相关个股有Vivani Medical Inc、Adial Pharmaceuticals Inc、Vtv Therapeutics Inc,振幅分别为424.75%、219.84%、121.41%。Cellectar Biosciences Inc公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402290050587a47c9fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402290050587a47c9fa&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2414808408","title":"Cellectar Biosciences Inc盘中异动 快速上涨5.15%报3.67美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2414808408","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2414808408?lang=zh_cn&edition=full","pubTime":"2024-02-27 22:32","pubTimestamp":1709044353,"startTime":"0","endTime":"0","summary":"北京时间2024年02月27日22时32分,Cellectar Biosciences Inc股票出现异动,股价大幅上涨5.15%。Cellectar Biosciences Inc股票所在的生物技术行业中,整体跌幅为0.28%。Cellectar Biosciences Inc公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。其领先的PDC治疗,iopofosine是一种小分子PDC,旨在提供碘-131直接靶向传输到癌细胞,同时限制其暴露于健康细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402272232347a4752f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402272232347a4752f0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413110532","title":"Cellectar Biosciences Inc盘中异动 早盘急速上涨5.04%报3.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2413110532","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2413110532?lang=zh_cn&edition=full","pubTime":"2024-02-22 22:38","pubTimestamp":1708612682,"startTime":"0","endTime":"0","summary":"北京时间2024年02月22日22时38分,Cellectar Biosciences Inc股票出现波动,股价急速拉升5.04%。Cellectar Biosciences Inc股票所在的生物技术行业中,整体涨幅为0.85%。Cellectar Biosciences Inc公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。其领先的PDC治疗,iopofosine是一种小分子PDC,旨在提供碘-131直接靶向传输到癌细胞,同时限制其暴露于健康细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022222380287e7241c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022222380287e7241c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413869114","title":"Cellectar Biosciences Inc盘中异动 快速下挫5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2413869114","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2413869114?lang=zh_cn&edition=full","pubTime":"2024-02-21 02:21","pubTimestamp":1708453269,"startTime":"0","endTime":"0","summary":"北京时间2024年02月21日02时21分,Cellectar Biosciences Inc股票出现波动,股价急速跳水5.08%。Cellectar Biosciences Inc股票所在的生物技术行业中,整体跌幅为0.88%。Cellectar Biosciences Inc公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。其领先的PDC治疗,iopofosine是一种小分子PDC,旨在提供碘-131直接靶向传输到癌细胞,同时限制其暴露于健康细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240221022110861d687b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240221022110861d687b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411366235","title":"Cellectar Biosciences Inc盘中异动 下午盘股价大涨5.31%报3.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2411366235","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2411366235?lang=zh_cn&edition=full","pubTime":"2024-02-15 04:23","pubTimestamp":1707942209,"startTime":"0","endTime":"0","summary":"北京时间2024年02月15日04时23分,Cellectar Biosciences Inc股票出现波动,股价急速上涨5.31%。截至发稿,该股报3.57美元/股,成交量50.7216万股,换手率4.13%,振幅4.60%。Cellectar Biosciences Inc股票所在的生物技术行业中,整体涨幅为1.08%。Cellectar Biosciences Inc公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。其领先的PDC治疗,iopofosine是一种小分子PDC,旨在提供碘-131直接靶向传输到癌细胞,同时限制其暴露于健康细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240215042329861d5474&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240215042329861d5474&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411739896","title":"Cellectar Biosciences Inc盘中异动 下午盘快速下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2411739896","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2411739896?lang=zh_cn&edition=full","pubTime":"2024-02-14 02:14","pubTimestamp":1707848052,"startTime":"0","endTime":"0","summary":"北京时间2024年02月14日02时14分,Cellectar Biosciences Inc股票出现波动,股价快速下挫5.00%。Cellectar Biosciences Inc股票所在的生物技术行业中,整体跌幅为1.06%。其相关个股中,Pasithea Therapeutics Corp C/Wts 12/08/2026 、Ocean Biomedical Inc C/Wts 14/02/2028 、Tc Biopharm Plc C/Wts 10/02/2028 涨幅较大,Biodexa Pharmaceuticals Plc、Revelation Biosciences Inc、Adial Pharmaceuticals Inc较为活跃,换手率分别为426.26%、212.99%、128.99%,振幅较大的相关个股有Cingulate Inc C/Wts 10/12/2026 、Renovaro Biosciences Inc、Calidi Biotherapeutics Inc,振幅分别为53.85%、51.26%、50.00%。Cellectar Biosciences Inc公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240214021413861d51c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240214021413861d51c0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2409435162","title":"Cellectar Biosciences Inc盘中异动 股价大跌5.05%报3.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2409435162","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2409435162?lang=zh_cn&edition=full","pubTime":"2024-02-05 22:58","pubTimestamp":1707145116,"startTime":"0","endTime":"0","summary":"北京时间2024年02月05日22时58分,Cellectar Biosciences Inc股票出现异动,股价急速下挫5.05%。Cellectar Biosciences Inc股票所在的生物技术行业中,整体涨幅为0.42%。其相关个股中,4D Molecular Therapeutics Inc、180 Life Sciences Corp C/Wts 07/11/2025、Adverum Biotechnologies Inc涨幅较大,Biorestorative Therapies Inc、Genprex Inc、Revelation Biosciences Inc较为活跃,换手率分别为222.68%、73.24%、58.79%,振幅较大的相关个股有180 Life Sciences Corp C/Wts 07/11/2025、Adverum Biotechnologies Inc、4D Molecular Therapeutics Inc,振幅分别为289.47%、35.92%、31.39%。Cellectar Biosciences Inc公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240205225837790f4164&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240205225837790f4164&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2408314980","title":"Cellectar Biosciences Inc盘中异动 股价大跌5.34%报3.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2408314980","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2408314980?lang=zh_cn&edition=full","pubTime":"2024-02-02 23:09","pubTimestamp":1706886568,"startTime":"0","endTime":"0","summary":"北京时间2024年02月02日23时09分,Cellectar Biosciences Inc股票出现波动,股价大幅下跌5.34%。Cellectar Biosciences Inc股票所在的生物技术行业中,整体跌幅为0.76%。Cellectar Biosciences Inc公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。其领先的PDC治疗,iopofosine是一种小分子PDC,旨在提供碘-131直接靶向传输到癌细胞,同时限制其暴露于健康细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240202230929790ea4b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240202230929790ea4b6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2407393261","title":"Cellectar Biosciences Inc盘中异动 股价大跌5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2407393261","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2407393261?lang=zh_cn&edition=full","pubTime":"2024-01-31 01:43","pubTimestamp":1706636595,"startTime":"0","endTime":"0","summary":"北京时间2024年01月31日01时43分,Cellectar Biosciences Inc股票出现异动,股价大幅跳水5.23%。Cellectar Biosciences Inc股票所在的生物技术行业中,整体跌幅为0.23%。其相关个股中,Neximmune Inc、Pepgen Inc、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大,Neximmune Inc、Panbela Therapeutics Inc、Gri Bio Inc较为活跃,换手率分别为1310.49%、265.68%、183.44%,振幅较大的相关个股有Psyence Biomedical Ltd、Neximmune Inc、Gri Bio Inc,振幅分别为800.00%、218.65%、89.01%。Cellectar Biosciences Inc公司简介:Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240131014315861cf023&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240131014315861cf023&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cellectar.com","stockEarnings":[{"period":"1week","weight":0.0284},{"period":"1month","weight":0.0258},{"period":"3month","weight":0.4368},{"period":"6month","weight":0.5076},{"period":"1year","weight":1.8633},{"period":"ytd","weight":0.4368}],"compareEarnings":[{"period":"1week","weight":0.0017},{"period":"1month","weight":0.0318},{"period":"3month","weight":0.1005},{"period":"6month","weight":0.2236},{"period":"1year","weight":0.3033},{"period":"ytd","weight":0.1005}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cellectar Biosciences, Inc.以前名为Novelos Therapeutics, Inc.于1996年6月成立于特拉华州。2014年2月11日,公司更名为现在的名字。它是一家生物制药公司,开发用于治疗肿瘤成像化合物。该公司的癌症靶向技术允许选择性递送的多种剂对癌症细胞,包括癌症干细胞。该公司目前正在开发三种专利的候选产品:I-124-CLR1404 是一种小分子,广谱,肿瘤的靶向性的正电子发射断层扫描(PET)显像剂,该公司认为其必须在范围广泛的癌症肿瘤和转移的选择性检测的第一种可能。I-131-CLR1404是一种小分子,广谱,癌靶向分子放射治疗的直接和选择性地提供细胞毒性(细胞杀伤)辐射到癌细胞和癌干细胞。CLR1502是一种临床前,小分子,肿瘤靶向,非放射性的光学成像术中肿瘤边缘照明和非侵入性的肿瘤成像剂。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.027916},{"month":2,"riseRate":0.6,"avgChangeRate":0.012926},{"month":3,"riseRate":0.5,"avgChangeRate":-0.02847},{"month":4,"riseRate":0.222222,"avgChangeRate":-0.081072},{"month":5,"riseRate":0.333333,"avgChangeRate":0.052545},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.058603},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.066667},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.019682},{"month":9,"riseRate":0.4,"avgChangeRate":-0.041969},{"month":10,"riseRate":0.1,"avgChangeRate":-0.147573},{"month":11,"riseRate":0.4,"avgChangeRate":-0.05683},{"month":12,"riseRate":0.4,"avgChangeRate":0.02288}],"exchange":"NASDAQ","name":"Cellectar Biosciences Inc.","nameEN":"Cellectar Biosciences"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cellectar Biosciences Inc.(CLRB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Cellectar Biosciences Inc.(CLRB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Cellectar Biosciences Inc.,CLRB,Cellectar Biosciences Inc.股票,Cellectar Biosciences Inc.股票老虎,Cellectar Biosciences Inc.股票老虎国际,Cellectar Biosciences Inc.行情,Cellectar Biosciences Inc.股票行情,Cellectar Biosciences Inc.股价,Cellectar Biosciences Inc.股市,Cellectar Biosciences Inc.股票价格,Cellectar Biosciences Inc.股票交易,Cellectar Biosciences Inc.股票购买,Cellectar Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cellectar Biosciences Inc.(CLRB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Cellectar Biosciences Inc.(CLRB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}